Recursion Pharmaceuticals
RXRX
RXRX
320 hedge funds and large institutions have $1.58B invested in Recursion Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 130 increasing their positions, 76 reducing their positions, and 50 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
less first-time investments, than exits
New positions opened: | Existing positions closed:
1.76% less ownership
Funds ownership: 77.61% → 75.85% (-1.8%)
3% less funds holding
Funds holding: 331 → 320 (-11)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
Holders
320
Holding in Top 10
8
Calls
$52.4M
Puts
$30.7M
Top Buyers
| 1 | +$34.6M | |
| 2 | +$18.1M | |
| 3 | +$16.4M | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$10.7M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.02M |
Top Sellers
| 1 | -$11.5M | |
| 2 | -$8.47M | |
| 3 | -$4.28M | |
| 4 |
Millennium Management
New York
|
-$3.74M |
| 5 |
LIP
Liontrust Investment Partners
London,
United Kingdom
|
-$3.55M |
